Todd C. Brady, M.D., Ph.D., is a distinguished medical professional and scientist who currently serves as the President and Chief Executive Officer of Aldeyra Therapeutics Inc., a biotechnology company focused on developing novel therapies for immune-mediated diseases. Dr. Brady holds dual degrees in medicine and pharmacology, having earned his M.D. and Ph.D. from the University of Pennsylvania School of Medicine. His extensive educational background has equipped him with a deep understanding of both clinical and scientific aspects of drug development, making him a pivotal leader in the biotech industry. Before joining Aldeyra Therapeutics, Dr. Brady held several key positions in the pharmaceutical sector, where he gained invaluable experience in drug discovery and development. His career highlights include significant contributions to the development of treatments for various diseases, showcasing his ability to translate scientific research into tangible medical solutions. At Aldeyra Therapeutics, Dr. Brady has been instrumental in steering the company's strategic direction, leading the advancement of its product pipeline, and fostering a culture of innovation. Under his leadership, the company has made notable progress in clinical trials, particularly in the development of therapies targeting rare and immune-mediated diseases. Dr. Brady's role at Aldeyra Therapeutics extends beyond executive management; he is also deeply involved in the scientific aspects of the company's operations. His hands-on approach and commitment to advancing medical science have been crucial in driving the company's mission to improve patient outcomes. His leadership has been recognized within the industry, and he continues to be a respected figure in the field of biotechnology, dedicated to bringing innovative treatments to those in need.